Abstract: The present invention relates to compositions and their use in methods of protecting and maintaining oligodendrocytes, and of treating demyelinating disorders
Type:
Application
Filed:
September 30, 2021
Publication date:
March 31, 2022
Applicants:
Oncolmmune, Inc., Children's National Medical Center
Inventors:
Yang Liu, Pan Zheng, Martin Devenport, Ning Li
Abstract: The present invention relates to compositions of anti-CTLA-4 antibodies that bind to the human CTLA4 molecule and their use in cancer immunotherapy and for the reduction of autoimmune side effects compared to other immunotherapeutic agents.
Type:
Application
Filed:
January 29, 2019
Publication date:
February 18, 2021
Applicants:
Oncolmmune, Inc., Children's Research Institute, Children's National Medical Center
Inventors:
Yang Liu, Pan Zheng, Fei Tang, Mingyue Liu, Martin Devenport, Xuexiang Du, Yan Zhang
Abstract: This invention relates to anti-CTLA-4 antibody compositions that bind to the human CTLA-4 molecule, and the use of the compositions in cancer immunotherapy and for reducing autoimmune side effects compared to other immunotherapeutic agents.
Type:
Application
Filed:
January 29, 2019
Publication date:
February 11, 2021
Applicants:
Oncolmmune, Inc., University of Maryland, Baltimore
Inventors:
Yang Liu, Pan Zheng, Fei Tang, Mingyue Liu, Martin Devenport, Xuexiang Du, Yan Zhang
Abstract: Provided herein is a CD24 protein. The CD24 protein may include mature human or mouse CD24, as well as a N- or C-terminally fused portion of a mammalian immunoglobulin.
Type:
Application
Filed:
August 16, 2018
Publication date:
January 17, 2019
Applicant:
ONCOLMMUNE, INC.
Inventors:
Xincheng Zheng, Wei Wu, Yang Liu, Pan Zheng
Abstract: The present invention relates to treating a hematologic cancer using a Hypoxia-Inducible Factor (HIF inhibitor). The invention also relates to inducing acute myeloid leukemia remission using the HIF inhibitor. The invention further relates to inhibiting a maintenance or survival function of a cancer stem cell (CSC) using the HIF inhibitor.
Type:
Grant
Filed:
August 11, 2016
Date of Patent:
April 18, 2017
Assignee:
Oncolmmune, Inc.
Inventors:
Yang Liu, Yin Wang, Yan Liu, Sami N. Malek, Pan Zheng
Abstract: Provided herein is a CD24 protein. The CD24 protein may include mature human or mouse CD24, as well as a N- or C-terminally fused portion of a mammalian immunoglobulin.
Type:
Grant
Filed:
October 21, 2014
Date of Patent:
April 4, 2017
Assignee:
Oncolmmune, Inc.
Inventors:
Xincheng Zheng, Wei Wu, Yang Liu, Pan Zheng
Abstract: Provided herein is a CD24 protein. The CD24 protein may include mature human or mouse CD24, as well as a N- or C-terminally fused portion of a mammalian immunoglobulin.
Type:
Application
Filed:
October 21, 2014
Publication date:
August 27, 2015
Applicant:
Oncolmmune, Inc.
Inventors:
Xincheng Zheng, Wei Wu, Yang Liu, Pan Zheng